Hormone-related tumors in transsexuals receiving treatment with cross-sex hormones

European Journal of Endocrinology

Volumn 159, Issue 3, 2008, Pages 197-202

  Mueller, Andreas ^a   Gooren, Louis ^b  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANTIESTROGEN; AROMATASE; AROMATASE INHIBITOR; BRCA1 PROTEIN; ESTRADIOL; ESTROGEN; GESTAGEN; PROLACTIN; PROSTATE SPECIFIC ANTIGEN; SEX HORMONE; TESTOSTERONE; TESTOSTERONE 17BETA DEHYDROGENASE; TESTOSTERONE ENANTATE;

BLADDER CARCINOMA; BREAST CANCER; BREAST CARCINOGENESIS; BREAST CARCINOMA; BREAST FIBROADENOMA; BREAST METASTASIS; BREAST SELF EXAMINATION; CANCER GROWTH; CANCER RISK; COLON CANCER; DRUG MEGADOSE; DRUG SAFETY; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; ESTROGEN SYNTHESIS; FEMALE TO MALE TRANSSEXUAL; GENE MUTATION; GENETIC RISK; HORMONAL REGULATION; HORMONAL THERAPY; HORMONE BLOOD LEVEL; HORMONE SUBSTITUTION; HUMAN; HYPOPHYSIS ADENOMA; LUNG ADENOCARCINOMA; MALE TO FEMALE TRANSSEXUAL; MALIGNANT TRANSFORMATION; MAMMOGRAPHY; MASTECTOMY; MEDLINE; MENOPAUSE; OVARIECTOMY; OVARY CANCER; OVARY CARCINOMA; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTINOMA; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN BLOOD LEVEL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; ENDOMETRIUM TUMOR; FEMALE; HYPOPHYSIS TUMOR; MALE; NEOPLASM; OVARY TUMOR; PROSTATE TUMOR; TRANSSEXUALISM;

BREAST NEOPLASMS; ENDOMETRIAL NEOPLASMS; FEMALE; GONADAL STEROID HORMONES; HUMANS; MALE; NEOPLASMS, HORMONE-DEPENDENT; OVARIAN NEOPLASMS; PITUITARY NEOPLASMS; PROLACTINOMA; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; TRANSSEXUALISM;

EID: 53249145792     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/EJE-08-0289     Document Type: Review

References (47)

1. Gooren L. Hormone treatment of the adult transsexual patient. Hormone Research 2005 64 31-36.
2. Levy A, Crown A & Reid R. Endocrine intervention for transsexuals. Clinical Endocrinology 2003 59 409-418.
3. Moore E, Wisniewski A & Dobs A. Endocrine treatment of transsexual people: a review of treatment regimens, outcomes, and adverse effects. Journal of Clinical Endocrinology and Metabolism 2003 88 3467-3473.
4. Tangpricha V, Ducharme SH, Barber TW & Chipkin SR. Endocrinologic treatment of gender identity disorders. Endocrine Practice 2003 9 12-21.
5. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, Lane D, Langer RD, Lasser N, Lewis CE, Manson J, Margolis K, Ockene J, O'Sullivan MJ, Phillips L, Prentice RL, Ritenbaugh C, Robbins J, Rossouw JE, Sarto G, Stefanick ML, Van Horn L, Wactawski-Wende J, Wallace R & Wassertheil-Smoller S. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. Journal of American Medical Association 2004 291 1701-1712.
6. Ito K. Hormone replacement therapy and cancers: the biological roles of estrogen and progestin in tumorigenesis are different between the endometrium and breast. Tohoku Journal of Experimental Medicine 2007 212 1-12.
7. Ito K, Utsunomiya H, Suzuki T, Saitou S, Akahira J, Okamura K, Yaegashi N & Sasano H. 17β-hydroxysteroid dehydrogenases in human endometrium and its disorders. Molecular and Cellular Endocrinology 2006 248 136-140.
8. van Kesteren PJ, Gooren LJ & Megens JA. An epidemiological and demographic study of transsexuals in The Netherlands. Archives of Sexual Behaviour 1996 25 589-600.
9. van Kesteren PJ, Asscheman H, Megens JA & Gooren LJ. Mortality and morbidity in transsexual subjects treated with cross-sex hormones. Clinical Endocrinology 1997 47 337-342.
10. Gooren LJ, Assies J, Asscheman H, de Slegte R & van Kessel H. Estrogen-induced prolactinoma in a man. Journal of Clinical Endocrinology and Metabolism 1988 66 444-446.
11. Kovacs K, Stefaneanu L, Ezzat S & Smyth HS. Prolactin-producing pituitary adenoma in a male-to-female transsexual patient with protracted estrogen administration. A morphologic study. Archives in Pathology and Laboratory Medicine 1994 118 562-565.
12. Serri O, Noiseux D, Robert F & Hardy J. Lactotroph hyperplasia in an estrogen treated male-to-female transsexual patient. Journal of Clinical Endocrinology and Metabolism 1996 81 3177-3179.
13. Pritchard TJ, Pankowsky DA, Crowe JP & Abdul-Karim FW. Breast cancer in a male-to-female transsexual. A case report. Journal of American Medical Association 1988 259 2278-2280.
14. Ganly I & Taylor EW. Breast cancer in a trans-sexual man receiving hormone replacement therapy. British Journal of Surgery 1995 82 341.
15. Woolcott CG, Sengupta SK, Hanna WM & Aronson KJ. Estrogen and progesterone receptor levels in nonneoplastic breast epithelium of breast cancer cases versus benign breast biopsy controls. BMC Cancer 2008 8 130.
16. Henriksen KL, Sonne-Hansen K, Kirkegaard T, Frogne T & Lykkesfeldt AE. Development of new predictive markers for endocrine therapy and resistance in breast cancer. Acta Oncologica 2008 47 795-801.
17. Gibson LJ, Dawson CK, Lawrence DH & Bliss JM. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. Cochrane Database of Systematic Reviews, 2007 CD003370.
18. Lonning PE & Geisler J. Indications and limitations of third-generation aromatase inhibitors. Expert Opinions in Investigative Drugs 2008 17 723-739.
19. Tai YC, Domchek S, Parmigiani G & Chen S. Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. Journal of National Cancer Institute 2007 99 1811-1814.
20. Burcombe RJ, Makris A, Pittam M & Finer N. Breast cancer after bilateral subcutaneous mastectomy in a female-to-male transsexual. Breast 2003 12 290-293.
21. Nicolas Diaz-Chico B, German Rodriguez F, Gonzalez A, Ramirez R, Bilbao C, Cabrera de Leon A, Aguirre Jaime A, Chirino R, Navarro D & Diaz-Chico JC. Androgens and androgen receptors in breast cancer. Journal of Steroid Biochemistry and Molecular Biology 2007 105 1-15.
22. von Schoultz B. Androgens and the breast. Maturitas 2007 57 47-49.
23. Somboonporn W & Davis SR. Testosterone effects on the breast: implications for testosterone therapy for women. Endocrine Reviews 2004 25 374-388.
24. Key TJ, Appleby PN, Reeves GK, Roddam A, Dorgan JF, Longcope C, Stanczyk FZ, Stephenson HE Jr, Falk RT, Miller R, Schatzkin A, Allen DS, Fentiman IS, Key TJ, Wang DY, Dowsett M, Thomas HV, Hankinson SE, Toniolo P, Akhmedkhanov A, Koenig K, Shore RE, Zeleniuch-Jacquotte A, Berrino F, Muti P, Micheli A, Krogh V, Sieri S, Pala V, Venturelli E, Secreto G, Barrett-Connor E, Laughlin GA, Kabuto M, Akiba S, Stevens RG, Neriishi K, Land CE, Cauley JA, Kuller LH, Cummings SR, Helzsouer KJ, Alberg AJ, Bush TL, Comstock GW, Gordon GB, Miller SR & Longcope C. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. Journal of National Cancer Institute 2003 95 1218-1226.
25. The role of testosterone therapy in postmenopausal women: position statement of The North American Menopause Society. Menopause 2005 12 496-511; quiz 649.
26. van Kesteren P, Meinhardt W, van der Valk F, Geldof A, Megens J & Gooren L. Effects of estrogens only on the prostates of aging men. Journal of Urology 1996 156 1349-1353.
27. Goodwin WE & Cummings RH. Squamous metaplasia of the verumontanum with obstruction due to hypertrophy: long-term effects of estrogen on the prostate in an aging male-to-female transsexual. Journal of Urology 1984 131 553-554.
28. van Haarst EP, Newling DW, Gooren LJ, Asscheman H & Prenger DM. Metastatic prostatic carcinoma in a male-to-female transsexual. British Journal of Urology 1998 81 776.
29. Dorff TB, Shazer RL, Nepomuceno EM & Tucker SJ. Successful treatment of metastatic androgen-independent prostate carcinoma in a transsexual patient. Clinical Genitourinary Cancer 2007 5 344-346.
30. Thurston AV. Carcinoma of the prostate in a transsexual. British Journal of Urology 1994 73 217.
31. Kraywinkel K, Lehnert M, Semjonow A & Hense HW. Epidemiology of prostate cancer: Recent results from the Epidemiological Cancer Register of the District of Munster (Germany). Urologe A 2008 47 853-859.
32. Hage JJ, Dekker JJ, Karim RB, Verheijen RH & Bloemena E. Ovarian cancer in female-to-male transsexuals: report of two cases. Gynecologic Oncology 2000 76 413-415.
33. Dizon DS, Tejada-Berges T, Koelliker S, Steinhoff M & Granal CO. Ovarian cancer associated with testosterone supplementation in a female-to-male transsexual patient. Gynecologic and Obstetric Investigation 2006 62 226-228.
34. Spinder T, Spijkstra JJ, van den Tweel JG, Burger CW, van Kessel H, Hompes PG & Gooren LJ. The effects of long term testosterone administration on pulsatile luteinizing hormone secretion and on ovarian histology in eugonadal female to male transsexual subjects. Journal of Clinical Endocrinology and Metabolism 1989 69 151-157.
35. Chadha S, Pache TD, Huikeshoven JM, Brinkmann AO & van der Kwast TH. Androgen receptor expression in human ovarian and uterine tissue of long-term androgen-treated transsexual women. Human Pathology 1994 25 1198-1204.
36. Tuckerman EM, Okon MA, Li T & Laird SM. Do androgens have a direct effect on endometrial function? An in vitro study Fertility and Sterility 2000 74 771-779.
37. Jongen VH, Thijssen JH, Hollema H, Donker GH, Santema JG, Van der Zee AG & Heineman MJ. Is aromatase cytochrome P450 involved in the pathogenesis of endometrioid endometrial cancer? International Journal of Gynecological Cancer 2005 15 529-536.
38. Filho AM, Barbosa IC, Maia H Jr, Genes CC & Coutinho EM. Effects of subdermal implants of estradiol and testosterone on the endometrium of postmenopausal women. Gynecological Endocrinology 2007 23 511-517.
39. Zang H, Sahlin L, Masironi B, Eriksson E & Linden Hirschberg A. Effects of testosterone treatment on endometrial proliferation in postmenopausal women. Journal of Clinical Endocrinology and Metabolism 2007 92 2169-2175.
40. Zang H, Sahlin L, Masironi B & Hirschberg AL. Effects of testosterone and estrogen treatment on the distribution of sex hormone receptors in the endometrium of postmenopausal women. Menopause 2008 15 233-239.
41. Braunstein GD. Management of female sexual dysfunction in postmenopausal women by testosterone administration: safety issues and controversies. Journal of Sexual Medicine 2007 4 859-866.
42. Lacey JV Jr, Brinton LA, Lubin JH, Sherman ME, Schatzkin A & Schairer C. Endometrial carcinoma risks among menopausal estrogen plus progestin and unopposed estrogen users in a cohort of postmenopausal women. Cancer Epidemiology, Biomarkers and Prevention 2005 14 1724-1731.
43. Doherty JA, Cushing-Haugen KL, Saltzman BS, Voigt LF, Hill DA, Beresford SA, Chen C & Weiss NS. Long-term use of postmenopausal estrogen and progestin hormone therapies and the risk of endometrial cancer. American Journal of Obstetrics and Gynaecology 2007 197 139 e1-7.
44. Mueller A, Kiesewetter F, Binder H, Beckmann MW & Dittrich R. Long-term administration of testosterone undecanoate every 3 months for testosterone supplementation in female-to-male transsexuals. Journal of Clinical Endocrinology and Metabolism 2007 92 3470-3475.
45. Dougherty SM, Mazhawidza W, Bohn AR, Robinson KA, Mattingly KA, Blankenship KA, Huff MO, McGregor WG & Klinge CM. Gender difference in the activity but not expression of estrogen receptors alpha and beta in human lung adenocarcinoma cells. Endocrine-Related Cancer 2006 13 113-134.
46. Slattery ML, Sweeney C, Murtaugh M, Ma KN, Caan BJ, Potter JD & Wolff R. Associations between vitamin D, vitamin D receptor gene and the androgen receptor gene with colon and rectal cancer. International Journal of Cancer 2006 118 3140-3146.
47. Wigertz A, Lonn S, Mathiesen T, Ahlbom A, Hall P & Feychting M. Risk of brain tumors associated with exposure to exogenous female sex hormones. American Journal of Epidemiology 2006 164 629-636.